Skip to main content
Bellicum Pharmaceuticals, Inc.Portfolio

Bellicum Pharmaceuticals, Inc.: Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

By December 1, 2018March 9th, 2021No Comments